FGL2 and melanoma: By querying scRNA-seq data of many human cancer types, including ovarian, melanoma, lung, breast and colorectal, we have shown that FGL2 is not expressed in cancer cells, but rather multiple immune and stromal cell types in the TME, with predominant expression in monocytes and macrophages.